Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Deterra Royalties (DRR.AX)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (A$) Price Target (A$) Rating
2022-02-164.544.20Neutral
2022-02-244.334.10Neutral
2022-03-254.674.40Neutral
2022-07-064.054.10Neutral
2022-08-184.584.75Neutral
2022-10-044.094.25Neutral
2022-12-134.564.75Neutral
2023-02-274.414.35Neutral
2023-04-184.784.40Sell
2023-06-274.534.10Sell
2023-08-164.503.90Sell
2023-10-064.744.80Neutral
2023-12-135.105.00Neutral
2024-04-094.764.80Neutral
2024-07-054.144.90Buy
2024-07-293.904.80Buy
2024-10-153.965.30Buy
2024-12-093.854.95Buy
2025-01-154.024.90Buy
2025-02-273.584.20Buy
2025-04-153.473.70Neutral

Disclosures

  • Because this security exhibits higher-than-average volatility, the FSR has been set at 15% above the MRA for a Buy rating, and at -15% below the MRA for a Sell rating (compared with 6/-6% under the normal rating system).
  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.